Next Article in Journal
Global Community Child Health
Next Article in Special Issue
Exposure to Environmental Tobacco Smoke (ETS) among Employees of Hospitality Venues in the Light of Changes in Anti-Tobacco Legislation in Poland
Previous Article in Journal
The Application of the Teaching Games for Understanding in Physical Education. Systematic Review of the Last Six Years
Previous Article in Special Issue
Association between Living with Children and the Health and Health Behavior of Women and Men. Are There Differences by Age? Results of the “German Health Update” (GEDA) Study
 
 
Article

In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters

1
Department of Medicine, The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz, Nowy Šwiat 4, 62-800 Kalisz, Poland
2
District Sanitary-Epidemiological Station in Jarocin, Waska 2, 63-200 Jarocin, Poland
3
State Hospital Jarocin, Szpitalna 1, 63-200 Jarocin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2020, 17(9), 3332; https://doi.org/10.3390/ijerph17093332
Received: 17 April 2020 / Revised: 2 May 2020 / Accepted: 8 May 2020 / Published: 11 May 2020
A variety of activities potentially contribute to the beneficial effects of probiotic bacteria observed in humans. Among these is a direct inhibition of the growth of pathogenic bacteria in the gut. The present study characterizes head-to-head the in-vitro pathogen growth inhibition of clinically relevant infectious bacterial strains by different types of probiotics and a synbiotic. In-vitro growth inhibition of Escherichia (E.) coli EPEC, Shigella (Sh.) sonnei, Salmonella (S.) typhimurium, Klebsiella (K.) pneumoniae and Clostridioides (C.) difficile were determined. Investigated products were a yeast mono strain probiotic containing Saccharomyces (Sac.) boulardii, bacterial mono strain probiotics containing either Lactobacillus (L.) rhamnosus GG or L. reuteri DSM 17938, a multi strain probiotic containing three L. rhamnosus strains (E/N, Oxy, Pen), and a multi strain synbiotic containing nine different probiotic bacterial strains and the prebiotic fructooligosaccharides (FOS). Inhibition of pathogens was moderate by Sac. boulardii and L. rhamnosus GG, medium by L. reuteri DSM 17938 and the L. rhamnosus E/N, Oxy, Pen mixture and strong by the multi strain synbiotic. Head-to-head in-vitro pathogen growth inhibition experiments can be used to differentiate products from different categories containing probiotic microorganisms and can support the selection process of products for further clinical evaluation. View Full-Text
Keywords: gut microbiome; antimicrobial activity; pathogen overgrowth gut microbiome; antimicrobial activity; pathogen overgrowth
Show Figures

Figure 1

MDPI and ACS Style

Piatek, J.; Krauss, H.; Ciechelska-Rybarczyk, A.; Bernatek, M.; Wojtyla-Buciora, P.; Sommermeyer, H. In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters. Int. J. Environ. Res. Public Health 2020, 17, 3332. https://doi.org/10.3390/ijerph17093332

AMA Style

Piatek J, Krauss H, Ciechelska-Rybarczyk A, Bernatek M, Wojtyla-Buciora P, Sommermeyer H. In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters. International Journal of Environmental Research and Public Health. 2020; 17(9):3332. https://doi.org/10.3390/ijerph17093332

Chicago/Turabian Style

Piatek, Jacek, Hanna Krauss, Arleta Ciechelska-Rybarczyk, Malgorzata Bernatek, Paulina Wojtyla-Buciora, and Henning Sommermeyer. 2020. "In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters" International Journal of Environmental Research and Public Health 17, no. 9: 3332. https://doi.org/10.3390/ijerph17093332

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop